<DOC>
	<DOCNO>NCT01601483</DOCNO>
	<brief_summary>This Phase II/III vehicle control , double mask , single center study . A single eye 60 individual mild moderate nonexudative Age-Related Macular Degeneration ( AMD ) randomly assign receive either topical 1 % MC-1101 vehicle control 2 year . The study design ass efficacy , safety , tolerability MC-1101 patient . An analysis primary secondary endpoint conduct subject complete 12 , 18 24 month .</brief_summary>
	<brief_title>Efficacy Safety Study MC-1101 1 % TID Treatment Nonexudative Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Males female age ≥ 50 year ≤ 85 year ; Females must least 1 year postmenopausal ( last menstrual period ) sterilize ; Better 20/80 ETDRS best correct visual acuity ; Mild moderate nonexudative AMD ( AMD step 3 8 AgeRelated Eye Disease Study ( AREDS ) Report No . 17 grade scale ) ; Willing sign inform consent , comply study protocol requirement , undergo 2.5 hour test visit ; Past current exudative AMD geographic atrophy ( fundus autofluorescence ) study eye ; Past current retinal choroidal vasculopathy study eye ( e.g . pigment epithelial detachment , polypoidal choroidal vasculopathy , central serous retinopathy , retinal vein occlusion , sickle cell retinopathy ) ; Uncontrolled hypertension ( ≥ 150 systolic ≥95 diastolic ) ; Diabetes mellitus ; Glaucoma ; Lens opacity ≥ grade 3 ARLNS standard photograph ; Unable complete biophysical testing ; Unable give inform consent ; Dilated pupil diameter le 6 millimeter ; Subjects history hypersensitivity reaction study drug agent use component study assessment ; Use topical ocular medication ( artificial tear product ) ; Anticipated extra intraocular intervention study period ; High myopia ( refractive error spherical equivalent ≥ 6 diopter ) ; Optic neuropathy ; Neurological condition impair vision ( e.g . Parkinson 's disease , multiple sclerosis , Alzheimer 's disease ) ; Liver disease ( e.g . cirrhosis , hepatitis ) ; History GI surgery ( e.g . bariatric surgery ) ; Unwilling unable take AREDS formula vitamin ( without betacarotene/vitamin A ) ; Current past use chloroquine , hydroxychloroquine , chlorpromazine , thioridazine , quinine sulfate , clofazimine , cisplatin , carmustine ( BCNU ) , deferoxamine ; Tobacco smoking ( currently within past 5 year ) ; Contact lens wearer ( prepared discontinue lens use ) ; Ophthalmic surgery kind within 3 month prior screen visit ; Participation interventional clinical study require IRB approval within 3 month enrollment ; Currently treat cancer disease likely adversely affect participation 2 year study ; Known AIDS/HIV</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>AMD</keyword>
	<keyword>Dry AMD</keyword>
	<keyword>Nonexudative AMD</keyword>
	<keyword>MC-1101</keyword>
</DOC>